It’s that time of the year again, and providers want to keep you and your family healthy during cold and flu season. “The ...

AN unlikely health issue becomes more risky when the days become shorter. Falls increase in the winter, thanks to less light, ...

Atricure, Inc. (($ATRC)) announced an update on their ongoing clinical study. Study Overview: The HEAL-IST IDE Trial, officially titled ‘Hybrid ...

The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.

Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only ...